SPDR S&P Biotech ETF Options Spot-On: On September 17th, 82,840 Contracts Were Traded, With 904.7K Open Interest
On September 17th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 82,840 options for the day, of which put options accounted for 33.05% of the total
What the Options Market Tells Us About Viking Therapeutics
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Biomarin Pharmaceutical Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
Regeneron Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M
Natera Shares Are Trading Higher After the Company Announced the Publication of Three Peer-reviewed Papers, Resulting in Over 85 Peer-reviewed Publications on Its Cancer Diagnostic Test Signatera
Exas Science Shares Are Trading Higher After the Company Announced Data for Its Blood-based Colorectal Cancer Screening Test.
Don't just focus on the polls! The trend of the US stock market is the compass for the US presidential election. Here is an investment guide for you to check out.
Analysts have found that since 1984, as long as the S&P 500 index rises accumulatively between August and October, the ruling party will win the election; on the contrary, if the S&P 500 index drops during this period, the challenger will win.
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
SPDR S&P Biotech ETF Options Spot-On: On September 13th, 100.9K Contracts Were Traded, With 867.18K Open Interest
On September 13th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 100.9K options for the day, of which put options accounted for 56.66% of the total
Canaccord Genuity Maintains Buy on Exact Sciences, Maintains $75 Price Target
Regeneron Pharmaceuticals And Sanofi Announce FDA Approval For Dupixent In The U.S. As First And Only Treatment For Adolescents With Chronic Rhinosinusitis With Nasal Polyps
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Piper Sandler Reiterates Overweight on Natera, Maintains $150 Price Target